Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Uveal Melanoma 1Neoplasm Metastasis 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × sotrastaurin × Clear all
NCT01402440 2020-12-19

Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma

Novartis

Phase 1 Terminated
15 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01430416 2020-12-19

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Novartis

Phase 1 Completed
153 enrolled
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT01854606 2020-12-19

COEB071X2103

Novartis

Phase 1 Completed
31 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡